Chen YH, Farnham PG, Hicks KA, Sansom SL. Estimating the HIV effective reproduction number in the United States and evaluating HIV elimination strategies. J Public Health Manag Pract. 2022 Mar;28(2). doi: 10.1097/PHH.0000000000001397
Lewis JH, Whelihan K, Roy D, White EJ, Morgan C, Vora RS, Boyle KR, Luebbering C, Bay RC, Lindley MC. Vaccination capability inventory of community, migrant, and homeless health centers: a survey report. J Public Health Manag Pract. 2020 Mar;26(2):139-47. doi: 10.1097/PHH.0000000000001073
Cazzell S, Moyer P, Samsell B, Dorsch K, McLean J, Moore M. A prospective, multicenter, single-arm clinical trial for treatment of complex diabetic foot ulcers with deep exposure using acellular dermal matrix. Adv Skin Wound Care. 2019 Sep;32(9):409-15. doi: 10.1097/01.ASW.0000569132.38449.c0
Jacobson EU, Hicks KA, Tucker EL, Farnham PG, Sansom SL. Effects of reaching national goals on HIV incidence, by race and ethnicity, in the United States. J Public Health Manag Pract. 2018 Jul;24(4):E1-8. doi: 10.1097/PHH.0000000000000717
Wilson M, Lucas A, Cameron A, Luo M. Budget impact of adding vedolizumab to a health plan formulary as a first-line biologic option for ulcerative colitis and crohn's disease. Am Health Drug Benefits. 2018 Jul;11(5):253-62.
Cainzos-Achirica M, Bilal U, Kapoor K, Quispe Ayala R, McEvoy JW, Pladevall-Vila M, Blumenthal RS, Blaha MJ. Methodological issues in nutritional epidemiology research–sorting through the confusion. Current Cardiovascular Risk Reports. 2018 Feb;12:4. doi: 10.1007/s12170-018-0567-8
Candrilli SD, Meyers JL, Boye K, Bae JP. Health care resource utilization and costs during episodes of care for type 2 diabetes mellitus-related comorbidities. J Diabetes Complications. 2015 May;29(4):529-33. doi: 10.1016/j.jdiacomp.2014.12.009
Cilenti D, Kum HC, Wells R, Whitmire JT, Goyal RK, Hillemeier MM. Changes in North Carolina maternal health service use and outcomes among medicaid-enrolled pregnant women during state budget cuts. J Public Health Manag Pract. 2015 Mar;21(2):208-13. doi: 10.1097/PHH.0000000000000118
Harris JB, Ward MA, Schwab P. Is response-guided therapy being applied in the clinical setting? The hepatitis C example. Am Health Drug Benefits. 2015 Feb;8(1):22-8.
Sacco P, Capkun-Niggli G, Zhang X, Jose R. The economic burden of fragile x syndrome: healthcare resource utilization in the United States. Am Health Drug Benefits. 2013 Mar;6(2):73-83.
Lennert B, Bibeau W, Farrelly E, Sacco P, Schoor T. Assessment of treatment patterns and patient outcomes in levodopa-induced dyskinesias (ASTROID): a US chart review study. Am Health Drug Benefits. 2012 Sep;5(6):347-58.
Cho BH, Hicks KA, Honeycutt AA, Hupert N, Khavjou O, Messonnier M, Washington ML. A Tool for the Economic Analysis of Mass Prophylaxis Operations With an Application to H1N1 Influenza Vaccination Clinics. J Public Health Manag Pract. 2011 Jan 1;17(1):E22-8.
Candrilli SD, Davis KL, Kan HJ, Lucero MA, Rousculp MD. Prevalence and the associated burden of illness of symptoms of diabetic peripheral neuropathy and diabetic retinopathy. J Diabetes Complications. 2007 Oct 1;21(5):306-14.